In brief
Quantum BioPharma Ltd. says its Lucid-MS drug candidate is preparing to move into Phase 2 clinical trials after Phase 1 studies assessed safety and tolerability. The candidate is being developed as a neuroprotective approach intended to protect myelin, rather than primarily targeting the immune system, and the company cites preclinical findings involving myelin degradation. The announcement also describes Quantum BioPharma’s work with researchers at Massachusetts General Hospital to assess a PET imaging method that could measure myelin integrity in people with multiple sclerosis. The company’s profile includes other assets and a separate UNBUZZD business arrangement, but the central update concerns Lucid-MS development and the imaging collaboration.
Key takeaways
- Lucid-MS is preparing for Phase 2 trials after Phase 1 safety and tolerability studies, according to the company.
- The candidate is being developed as a neuroprotective therapy for myelin damage associated with multiple sclerosis.
- Quantum BioPharma is collaborating with Massachusetts General Hospital researchers on a PET imaging technique to assess myelin integrity.
This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), was featured in a BioMedWire editorial highlighting its development of Lucid-MS, a patented, first-in-class drug candidate designed to directly protect the myelin sheath damaged by multiple sclerosis. Unlike conventional MS treatments that primarily target the immune system, Lucid-MS is being developed as a non-immunomodulatory neuroprotective therapy and is preparing to enter Phase 2 clinical trials following successful Phase 1 safety and tolerability studies.
The editorial notes that Lucid-MS has demonstrated the ability to prevent and reverse myelin degradation in preclinical studies and is supported by more than a decade of scientific research. Quantum BioPharma is also advancing a collaboration with researchers at Massachusetts General Hospital to validate a novel PET imaging technique that may enable direct measurement of myelin integrity in MS patients. The feature additionally highlighted developments across the neurological and immune-mediated disease sectors, including programs from Sanofi (NASDAQ: SNY), Roche Holding AG (OTCQX: RHHBY), Biogen Inc. (NASDAQ: BIIB) and Clene Inc. (NASDAQ: CLNN).
To view the full press release, visit https://ibn.fm/iZmx1
About Quantum BioPharma Ltd.
Quantum is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum invented UNBUZZD(TM) and spun out its OTC version to a company, Unbuzzd Wellness Inc. (“Unbuzzd”) (formerly, Celly Nutrition Corp.), led by industry veterans. Quantum retains ownership of 19.84% (as of March 31, 2026) of Unbuzzd at www.unbuzzd.com. The agreement with Unbuzzd also includes royalty payments of 7% of sales from unbuzzd(TM) until payments to Quantum total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]
Questions around this news
What is Lucid-MS and what is it being developed to do?
The release describes Lucid-MS as a patented drug candidate intended to protect myelin, the sheath damaged in multiple sclerosis. It says preclinical studies showed the candidate could prevent and reverse myelin degradation. The therapy is being developed as neuroprotective and non-immunomodulatory, rather than primarily targeting the immune system.
What is the planned PET imaging collaboration intended to evaluate?
The release says the company is working with researchers at Massachusetts General Hospital to validate a PET imaging technique that may allow direct measurement of myelin integrity in people with multiple sclerosis. It does not provide further details about the technique, study design, or validation timeline.
How does a neuroprotective treatment differ from an immunomodulatory treatment?
A neuroprotective treatment is intended to help preserve nerve cells or related structures from damage. An immunomodulatory treatment acts by changing the activity of the immune system. These describe different therapeutic aims; a treatment’s actual effects depend on its mechanism and clinical evidence.
